COVID-19 May Pose Blood Clot Risk in Pregnant Women

New Endocrinology cover

COVID-19 may increase the risk of blood clots in women who are pregnant or taking estrogen with birth control or hormone replacement therapy, according to a new manuscript published in the Endocrine Society’s journal, Endocrinology.

One of the many complications of COVID-19 is the formation of blood clots in previously healthy people. Estrogen increases the chance of blood clots during pregnancy and in women taking birth control pills or hormone replacement therapy. If infected with COVID-19, these women’s risk of blood clotting could be even higher, and they may need to undergo anticoagulation therapy or to discontinue their estrogen medicines.

“Research that helps us understand how the coronavirus causes blood clots may also provide us with new knowledge regarding how blood clots form in other settings and how to prevent them.” – Daniel I. Spratt, MD, of Maine Medical Center in Portland, Maine, and Tufts University School of Medicine in Boston, Mass.

“During this pandemic, we need additional research to determine if women who become infected with the coronavirus during pregnancy should receive anticoagulation therapy or if women taking birth control pills or hormone replacement therapy should discontinue them,” said the study’s corresponding author, Daniel I. Spratt, MD, of Maine Medical Center in Portland, Maine, and Tufts University School of Medicine in Boston, Mass. “Research that helps us understand how the coronavirus causes blood clots may also provide us with new knowledge regarding how blood clots form in other settings and how to prevent them.”

Researching and understanding the cause of blood clotting in COVID-19, including the intersecting effects of estrogen therapy or pregnancy, has several hurdles and will require innovative animal and tissue models.

Conversations between clinicians and basic researchers and between endocrinologists and hematologists are necessary to explore potential interactions between SARS-CoV-2—the virus that causes COVID-19—and pregnancy or estrogen therapy that could guide clinical management.

The manuscript’s co-author is Rachel J. Buchsbaum, MD, of Tufts Medical Center and Tufts University School of Medicine.

The manuscript received no external funding.

The manuscript, “COVID-19 and Hypercoagulability: Potential Impact on Management with Oral Contraceptives, Estrogen Therapy and Pregnancy,” was published online, ahead of print.

You may also like

  • Redefining Diabetes Care in Pregnancy

    New Endocrine Society and European Endocrine Society guidelines provide a much-needed update Making its debut at ENDO 2025, “Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline” has been long anticipated. For the first time, clinicians will have a definitive guide on treating these patients that now includes the…

  • Tightrope: Obesity Management in Women During Reproductive Years

    As part of the ENDO 2025 session, “Obesity Management Across the Lifespan: Special Considerations,” Lisa Morselli, MD, PhD, talks about the unique challenges in obesity management in women during their reproductive years. On Tuesday, July 15, ENDO 2025 here in San Francisco will feature a session titled, “Obesity Management Across the Lifespan: Special Considerations.” As…

Find more in